Tyrosine kinase inhibitors and interferon

Area of Science:

• Hematology
• Oncology
• Pharmacology

Background:

• Interferon-alpha (INF) was a breakthrough therapy for chronic myeloid leukemia (CML) in the 1980s, especially for patients ineligible for bone marrow transplantation.
• Imatinib, the first tyrosine kinase inhibitor (TKI), became the standard CML treatment based on the IRIS trial, supplanting INF.
• Combining INF with imatinib has been explored for enhanced therapeutic responses in CML patients.

Purpose of the Study:

• To investigate the combined use of second-generation TKIs with pegylated interferon (peg-IFN) in CML treatment.
• To minimize treatment failures in CML patients.
• To increase the number of CML patients achieving deep molecular responses, potentially allowing treatment cessation.

Main Methods:

• Review of existing literature on INF and TKI combinations in CML therapy.
• Analysis of clinical trial data regarding second-generation TKIs and peg-IFN.
• Evaluation of molecular response rates and treatment discontinuation in CML patients.

Main Results:

• Previous studies demonstrated efficacy of INF combined with imatinib.
• Current research focuses on optimizing combinations of newer TKIs with peg-IFN.
• The goal is to achieve deeper molecular remission and explore treatment-free remission in CML.

Conclusions:

• The combination of second-generation TKIs with peg-IFN represents a promising strategy for CML management.
• This approach aims to overcome TKI resistance and improve outcomes.
• Achieving deep molecular responses may facilitate treatment discontinuation for select CML patients.